Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its Q1 fiscal year 2024 financial results on November 14, 2023, before market open. A conference call and webcast to discuss the results, business strategy, partnerships, and regulatory processes will follow at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Conference Call Details:
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link: https://edge.media-server.com/mmc/p/mdyeh2j3

For further information, please contact:

Renalytix plc	www.renalytix.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)	Tel: 020 7710 7600
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker)	Tel: 020 7597 4000
Gary Clarence / Shalin Bhamra
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Alice Woodings	Mob: 07980 541 893 / 07407 804 654
CapComm Partners
Peter DeNardo	Tel: 415-389-6400 or investors@renalytix.com

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

FAQ

When will Renalytix plc report its financial results for Q1 fiscal year 2024?

Renalytix plc will report its Q1 fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open.

How can I participate in the conference call?

To participate in the live conference call via telephone, you can register at the provided link and upon registering, a dial-in number and unique PIN will be provided in order to join the conference call.

What topics will be discussed during the conference call?

The conference call will discuss the financial results, business strategy, partnerships, and regulatory and reimbursement processes.

How can I access the webcast?

You can access the webcast by registering at the provided link.